{"url_path":"/register/2026-05-15/2026-09808","section_key":"summary","section_title":"Government Owned Inventions Available for License: Synergistic Interactions for Improved Cancer Treatment","topic":"register","document":{"doc_type":"Notice","doc_date":"2026-05-15","source_url":"https://www.federalregister.gov/documents/2026/05/15/2026-09808/government-owned-inventions-available-for-license-synergistic-interactions-for-improved-cancer","accession_number":null,"cik":null,"ticker":null,"issuer_name":null,"edgar_url":null,"primary_entity_key":null,"primary_entity_name":"Health and Human Services Department"},"word_count":65,"has_tables":false,"body_markdown":"# Government Owned Inventions Available for License: Synergistic Interactions for Improved Cancer Treatment\n\n**Type:** Notice\n**Published:** 2026-05-15\n**Citation:** 91 FR 27968\n**Agencies:** Health and Human Services Department, National Institutes of Health\n**Source:** https://www.federalregister.gov/documents/2026/05/15/2026-09808/government-owned-inventions-available-for-license-synergistic-interactions-for-improved-cancer\n\n## Abstract\nThe National Cancer Institute (NCI) seeks research co- development partners and/or licensees to develop hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy into a therapeutic for cancer."}